Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma [7]

Leukemia and Lymphoma

Volumn 49, Issue 2, 2008, Pages 359-361

  Chumsri, Saranya ^a   Zhao, Merry ^a   Garofalo, Michael ^a   Burger, Angelika ^a   Hamburger, Anne ^a   Zhao, Frank ^a   Rapoport, Aaron ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; CD20 ANTIGEN; CD23 ANTIGEN; CD30 ANTIGEN; CD5 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACLIZUMAB; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; MAMMALIAN TARGET OF RAPAMYCIN; METHYLPREDNISOLONE; PENTOSTATIN; RAPAMYCIN; RITUXIMAB; SGN 30; T LYMPHOCYTE RECEPTOR;

AGED; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LETTER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN DEFECT; SKIN LYMPHOMA;

AGED; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SALVAGE THERAPY; SIROLIMUS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 38849123472     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701809214     Document Type: Letter

References (8)

1. Mamane, Y., Petroulakis, E., LeBacquer, O. and Sonenberg, N. (2006) mTOR, translation initiation and cancer. Oncogene, 25, pp. 6416-6422.
2. Easton, J. B. and Houghton, P. J. (2006) mTOR and cancer therapy. Oncogene, 25, pp. 6436-6446.
3. Hidalgo, M. and Rowinsky, E. K. (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19, pp. 6680-6686.
4. Baker, H., Sidorowicz, A., Sehgal, S. N. and Vezina, C. (1978) Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo), 31, pp. 539-545.
5. Assaf, C., Bagot, M., Dummer, R., Duvic, M., Gniadecki, R. and Knobler, R. (2006) Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: An expert opinion. Br J Dermatol, 155, pp. 261-266.
6. Song, J., Salek-Ardakani, S., So, T. and Croft, M. (2007) The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol, 8, pp. 64-73.
7. Zhang, Q., Nowak, I., Vonderheid, E. C., Rook, A. H., Kadin, M. E. and Nowell, P. C. (1996) Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA, 93, pp. 9148-9153.
8. Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, pp. 1098-1101.